Borstkanker Onderzoek Groep

• Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

  Collaborator, Phase 3, Recruiting, 220 people, 23 Aug 2022

• NCT05392608

  Phase 2, Active, not recruiting, 130 people, 26 May 2022

• NCT03532087

  Phase 2, Withdrawn, 0 people, 22 May 2018

• NCT03425838

  Phase 3, Active, not recruiting, 1,050 people, 8 Feb 2018

• Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.

  Phase 2, Active, not recruiting, 100 people, 14 Sept 2017

• NCT01996267

  Collaborator, Phase 3, Active, not recruiting, 437 people, 27 Nov 2013

• NCT01935492

  Phase 3, Completed, 420 people, 5 Sept 2013

• NCT01898117

  Collaborator, Phase 2, Active, not recruiting, 304 people, 12 Jul 2013

• NCT01099436

  Phase 3, Completed, 250 people, 7 Apr 2010

Sources: clinicaltrials.gov